Kimberly J. Manhard
Net Worth

Last updated:

What is Kimberly J. Manhard net worth?

The estimated net worth of Ms. Kimberly J. Manhard is at least $7,657,895 as of 13 Apr 2023. She owns shares worth $13,916 as insider, has earned $367,079 from insider trading and has received compensation worth at least $7,276,900 in Heron Therapeutics, Inc..

What is the salary of Kimberly J. Manhard?

Ms. Kimberly J. Manhard salary is $727,690 per year as Executive Vice President of Drug Devel. & Director in Heron Therapeutics, Inc..

How old is Kimberly J. Manhard?

Ms. Kimberly J. Manhard is 65 years old, born in 1960.

What stocks does Kimberly J. Manhard currently own?

As insider, Ms. Kimberly J. Manhard owns shares in one company:

Company Title Shares Price per share Total value
Heron Therapeutics, Inc. (HRTX) Executive Vice President of Drug Devel. & Director 10,872 $1.28 $13,916

What does Heron Therapeutics, Inc. do?

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

HRTX logo
HRTX
Heron Therapeutics, Inc.
$1.28

Kimberly J. Manhard insider trading

Heron Therapeutics, Inc.

Ms. Kimberly J. Manhard has made 14 insider trades between 2015-2023, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 24,000 units of HRTX stock on 29 Nov 2019. As of 13 Apr 2023 she still owns at least 10,872 units of HRTX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Sale
Common Stock 1,504 $4.76 $7,153
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 4,564 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 4,564 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Sale
Common Stock 1,529 $17.66 $27,008
Option
Common Stock 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Restricted Stock Units 1,250 N/A N/A
Option
Common Stock 1,250 N/A N/A
Option
Employee Stock Option (Right to Buy) 10,000 $13 $130,000
Option
Common Stock 10,000 $13 $130,000
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 1,158 N/A N/A
Option
Common Stock 24,000 $13 $312,000
Option
Employee Stock Option (Right to Buy) 24,000 $13 $312,000
Sale
Common Stock 24,000 $13 $312,000
Sale
Common Stock 1,109 $18.86 $20,918
Sale
Common Stock 494 N/A N/A
Sale
Common Stock 6,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 6,000 N/A N/A
Sale
Common Stock 6,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 6,000 N/A N/A
Option
Common Stock 6,000 N/A N/A
Option
Common Stock 18,000 N/A N/A
Sale
Common Stock 18,000 N/A N/A
Option
Employee Stock Option (Right to Buy) 18,000 N/A N/A
Sale
Common Stock 7,584 N/A N/A
Option
Employee Stock Option (Right to Buy) 7,584 N/A N/A
Option
Common Stock 7,584 N/A N/A
Option
Common Stock 21,542 $8.93 $192,262
Sale
Common Stock 21,542 N/A N/A
Option
Stock Option (Right to Buy) 5,250 N/A N/A
Option
Common Stock 21,542 N/A N/A
Option
Common Stock 10,500 N/A N/A
Sale
Common Stock 10,500 N/A N/A
Option
Stock Option (Right to Buy) 10,500 N/A N/A
Sale
Common Stock 2,708 N/A N/A
Option
Common Stock 2,708 N/A N/A
Option
Stock Option (Right to Buy) 2,708 N/A N/A

Heron Therapeutics key executives

Heron Therapeutics, Inc. executives and other stock owners filed with the SEC: